Asset Details
Do you wish to reserve the book?
The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope
Do you wish to request the book?
The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope
2017
Overview
Purpose of Review
Sarcomas are rare, heterogeneous group of soft tissue and bone tumors. Precise diagnosis of specific subtypes is challenging using conventional methods. Herein, we review the role of next-generation sequencing (NGS) technology that is used for rapid sequencing of DNA and RNA.
Recent Findings
Recent sarcoma specific studies recommend that molecular genetic testing should be added at diagnosis for appropriate clinical management in addition to diagnosis by expert pathologists. NGS has already been used to identify potentially actionable mutations, copy number alterations, and gene fusions. Rationally, choosing a drug based on an individual patient profile aka: “precision oncology” has been so far limited to few case reports in sarcomas.
Summary
As we improve our ability to deliver personalized medicine using all modalities including conventional therapy, more patients may eventually benefit. As the cost and capacity of NGS outpace Moore’s law, so does the probability of success.
